The acquired company, CymaBay Therapeutics, is a Newark, Calif.-based drug manufacturer focused on primary biliary cholangitis. PBC is a rare chronic liver disease that mainly affects women, with a prevalence of 130,000 people in the U.S.
Gilead’s purchase adds CymaBay’s lead drug candidate, seladelpar, to its portfolio, according to a Gilead news release. The FDA is reviewing seladelpar’s tentative approval, and its decision is expected by Aug. 14.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.